CC-AVI401-017XLSX
Source excerpt · Change!A1:C9
Havenor Therapeutics · Its newest medicine, Avericin, is finished and waiting for a health authority to approve it.
Task 02 · Head of CMC and MSAT
State the technical position on the alternate overwrap change
Give the engineering team’s position on what the proposed wrapper means for what was filed with the regulator.
GPT-6.1 Sol caught 7 of 12 traps. See which →
3What just happened?
A film supplier has proposed replacing the outer wrapper on Avericin’s bags.
The wrapper keeps oxygen away from the medicine. Because Avericin is under review, any change to its packaging may have to be reported to the regulator. The regulatory team wants the engineers’ view first.
Workspace cutoff date: 27 September 2026.
4Who has to do what?
Give the engineering team’s position on what the proposed wrapper means for what was filed with the regulator.
- The seat
- Jae Calder, Head of CMC and MSAT
- What a good answer looks like
- It keeps “proposed” and “approved” apart, compares the films on the property that matters (oxygen), and shows why a weaker barrier hits exactly the impurity that already limits shelf life.
- What must be handed in
CC-AVI401-017_CMC_regulatory_impact_brief.docx
The assignment as the model received it
Jonas needs CMC and MSAT’s technical position on CC-AVI401-017 for the Regulatory CMC impact discussion. Review the proposed alternate overwrap against the approved AVI-401 system and the evidence currently available. Write your position to _Working/Jae Calder/CC-AVI401-017_CMC_regulatory_impact_brief.docx.
5Which files decide it?
The supplier’s letter with its comparison table, the engineers’ draft assessment, the change status sheet, and the shelf-life data.
The model also has the rest of the company’s shared drive, its chat and its record systems. Finding the right files is part of the job. Flip through the key ones below.
Company documents
Some of the documents available to the model.
Change control · workbook
A change waiting for approval
The proposed film already has a material ID. This workbook shows how far the change has actually progressed.
The proposed material exists in the record. Quality approval has not been requested, and implementation is not authorized.
1 / 3
6What did the model do?
What GPT-6.1 Sol did, step by step.
In short: Sol keeps the proposed film separate from the approved system, focuses on oxygen rather than moisture, ties the weaker barrier to the impurity already limiting shelf life, and keeps the change in initial-review handling.
Step 6. Locates the overwrap change records and stability files. Sol searches the workspace for CC-AVI401-017, the supplier notification, the draft engineering assessment, and the AVI-401 stability records.
Tool call recorded in sessionconst r = await tools.exec_command({cmd:"pwd && rg --files -g 'AGENTS.md' -g '*A
Step 17. Reviews the validation and barrier records. Sol inspects the validation and packaging records to evaluate how the proposed HF-55 film bears on the Impurity A control strategy.
Tool call recorded in sessiontext((await tools.exec_command({cmd:"cat '/tmp/avi401-review/text/Laboratory/Spe
Step 28. Finalizes the impact brief, missing the ERP vs supplier-register gap. Sol connects the weaker oxygen barrier to the Impurity A shelf-life limit, but does not flag that Helion is absent from the approved supplier register while MAT-OWR-005 already exists in ERP.
Tool call recorded in sessiontext(await tools.exec_command({cmd:"python3 - <<'PY'\nfrom pypdf import PdfReade
Bears on: The new film lets in more oxygenMeasured at the wrong temperatureA letter and a draft prove nothing yetThe supplier graded its own homework
Replay every step of the run →
Inside the run
A
Model
Locates the overwrap change records and stability files
Model draft
const r = await tools.exec_command({cmd:"pwd && rg --files -g 'AGENTS.md' -g '*A
A
Sol searches the workspace for CC-AVI401-017, the supplier notification, the draft engineering assessment, and the AVI-401 stability records.
1 / 3
7Which traps did it catch?
It caught 7 of 12.
Specialists wrote these checks from the records in the workspace. Each is a weak spot a reviewer or inspector would find. A check passes only when the submitted file provides the required evidence.
Missed
The new film lets in more oxygen R02
At both reported conditions the new film lets through more oxygen: 2.1 vs 0.8, and 3.8 vs 2.4.
If missed, a weaker barrier is accepted as equal.
Measured at the wrong temperature R04
The supplier measured at 23 °C, not at the 25 °C / 60% humidity storage condition.
If missed, the comparison is stretched beyond what was actually measured.
A letter and a draft prove nothing yet R07
The supplier’s notification is just a letter and the assessment is an unapproved draft; neither makes the new film qualified.
If missed, paperwork in progress is treated as proof.
The supplier graded its own homework R09
The “new film is as good as the old one” comparison uses the new supplier’s numbers for both films. Nothing from the current supplier confirms the old film’s figure.
If missed, a weaker oxygen barrier could get through, and the medicine could break down before its expiry date.
“It fits” is only the supplier’s word R10
The supplier says its film fits the existing bag sizes, but Havenor’s own drawing of the part is still listed as missing.
If missed, wrappers that don’t fit could reach the packing line.
Caught
Proposed is not approved R01
The current wrapper film is the approved one. The new film is only proposed: on hold, not approved by Quality, not assessed by Regulatory, not authorized.
If missed, a proposal gets treated as a done deal.
Oxygen is what matters here R03
The impurity that limits shelf life forms when the medicine reacts with oxygen, so the new film’s better moisture barrier doesn’t make up for its worse oxygen barrier.
If missed, the films are compared on the wrong property.
The wrapper is part of the shelf-life evidence R05
The ongoing shelf-life study assumes the current wrapper. A weaker film needs new bridging tests before it can be used.
If missed, the shelf-life claim loses its support.
The sealing heat was never tried here R06
The supplier suggests a sealing temperature, but it has never run Havenor’s machines and there is no Havenor setting to compare against.
If missed, badly sealed wrappers could let oxygen in.
Old test results don’t cover the new film R08
The existing filter and container tests were done with the current wrapper. Whether they apply to the new film still has to be reviewed.
If missed, the new wrapper would be treated as tested when it never was.
Shelf life is already tight R11
The data already point to about 24 months against a 36-month claim. A film that lets in more oxygen acts on the very impurity that is setting that limit.
If missed, the riskiest possible change is handled like a routine one.
Still under initial review, not post-approval R12
Avericin is still under active marketing-application review, so post-approval variation categories do not apply yet and the regulatory reporting route belongs to Regulatory CMC.
If missed, the brief classifies the change under rules for an already-approved product.
Every model on the same job
One published attempt each, on the same assignment and checklist, so treat small gaps as noise.
- GPT-6.1 Sol · shown above7 / 12Run →
- Claude Opus 5.59 / 12Run →
- Claude Fable 5.19 / 12Run →
- GPT-6 Astra6 / 12Run →
Scores on this page are from the published biopharma-bench@v0.2 package (130 checks across these ten tasks).
Submitted document
CC-AVI401-017_CMC_regulatory_impact_brief.docx
1 / 8
Talk to usRequest the full Biopharma Bench V0.2, company environments and run receipts: team@raycaster.ai